Literature DB >> 18226436

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Midori Fujikawa1, Takashi Togo, Asuka Yoshimi, Junichi Fujita, Munetaka Nomoto, Atsushi Kamijo, Toru Amagai, Hirotake Uchikado, Omi Katsuse, Hideki Hosojima, Yoshihisa Sakura, Ryo Furusho, Akira Suda, Takayuki Yamaguchi, Taketo Hori, Ayuko Kamada, Taizo Kondo, Michitomo Ito, Toshinari Odawara, Yoshio Hirayasu.   

Abstract

Adherence to antipsychotic treatment is particularly important in the long-term management of schizophrenia and other related psychotic disorders since poor adherence to medication is associated with poor health outcomes. Although the patients' subjective satisfaction with the medication is crucial for adherence to medication, few studies have examined the relationship between subjective satisfaction with antipsychotics and adherence. In this study, we investigated subjective satisfaction with antipsychotics in patients with schizophrenia by using the Treatment Satisfaction Questionnaire for Medication (TSQM), a self-reporting instrument to assess the major dimensions of patients' satisfaction with their medication. The subjects included 121 clinically stabilized outpatients who met the following criteria: 1) patients between 20 and 65 years of age, diagnosed with schizophrenia or other psychotic disorders as defined by DSM-IV, 2) patients undergoing oral antipsychotic monotherapy or taking only an antiparkinsonian agent as an adjuvant remedy, and 3) patients who had received a stable dose of an antipsychotic for more than four weeks. Patients were asked to answer the TSQM questions, and their clinical symptoms were also evaluated by the Brief Psychiatric Rating Scale (BPRS). Satisfaction with regard to side-effects (p=0.015) and global satisfaction (p=0.035) were significantly higher in patients taking second-generation antipsychotics (SGAs, n=111) than those taking first-generation antipsychotics (FGAs, n=10), whereas no significant difference was found between the two groups in clinical symptoms according to BPRS (p=0.637) or the Drug-induced Extrapyramidal Symptoms Scale (DIEPSS, p=0.209). In addition, correlations were not significant between the subjective satisfactions and clinician-rated objective measures of the symptoms. These findings suggest that SGAs have more favorable subjective satisfaction profiles than FGAs in the treatment of schizophrenia. Since it is often difficult to detect the difference by a traditional objective assessment of the patients, it is desirable that physicians pay attention to the patients' subjective satisfaction in conjunction with their own objective clinical assessment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18226436     DOI: 10.1016/j.pnpbp.2007.12.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service.

Authors:  Inti Qurashi; Paul Stephenson; Simon Chu; Chris Duffy; Nusrat Husain; Imran Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

Review 2.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

3.  Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.

Authors:  Jun Soo Kwon; Sung Nyun Kim; Jaewook Han; Sang Ick Lee; Jae Seung Chang; Jung-Seok Choi; Heon-Jeong Lee; Seong Jin Cho; Tae-Youn Jun; Seung-Hwan Lee; Changsu Han; Kyoung-Uk Lee; Kyung Kyu Lee; EunJung Lee
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

4.  Perspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: a qualitative study.

Authors:  Iris Gault; Ann Gallagher; Mary Chambers
Journal:  Patient Prefer Adherence       Date:  2013-08-09       Impact factor: 2.711

5.  Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia.

Authors:  Alejandra Caqueo-Urízar; Alfonso Urzúa; Patricio Mena-Chamorro; Guillaume Fond; Laurent Boyer
Journal:  Patient Prefer Adherence       Date:  2020-09-03       Impact factor: 2.711

6.  Treatment satisfaction and its association with anxiety, depression and fear of COVID-19 among Lebanese inpatients with schizophrenia.

Authors:  Zeinab Bitar; Chadia Haddad; Sahar Obeid; Souheil Hallit
Journal:  Pharm Pract (Granada)       Date:  2021-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.